Compare WKEY & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | IMUX |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Switzerland | United States |
| Employees | 102 | 66 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 75.2M |
| IPO Year | N/A | 2013 |
| Metric | WKEY | IMUX |
|---|---|---|
| Price | $7.26 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.50 | $4.25 |
| AVG Volume (30 Days) | 64.8K | ★ 3.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.51 |
| 52 Week High | $19.80 | $1.51 |
| Indicator | WKEY | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 57.64 |
| Support Level | $6.24 | $0.64 |
| Resistance Level | $7.52 | N/A |
| Average True Range (ATR) | 0.43 | 0.13 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 37.43 | 46.99 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.